NCIS success rate for the Haematopoietic Stem Cell Transplant / Bone Marrow Transplant Programme is comparable to the international registry data at the Centre for International Blood & Marrow Transplant Research (CIBMTR) and the European Group for Blood and Marrow Transplant (EBMT).
| Type of transplant | Diagnosis | NCIS Success Rate | International Registry Success Rate | Reference |
|---|---|---|---|---|
| Matched Sibling Donor (MSD) Transplant | Acute Leukaemia | ~50% at 5 years (2005 - 2016) | ~50% at 5 years (2001 - 2018), CIBMTR | Cheryl Lim, Koh LP et al. EBMT 2017 |
| Matched Unrelated (Volunteer) Donor (MUD) Transplant | Acute Leukaemia | ~50% at 5 years (2005 - 2016) | ~50% at 5 years (2001 - 2018), CIBMTR | Cheryl Lim, Koh LP et al. EBMT 2017 |
| Unrelated Umbilical Cord Blood (UCB) Transplant | Haematological Cancers (Leukemia, Lymphoma, Myelodysplastic Syndromes) | ~50% at 3 years (2007 - 2019) | ~40% at 5 years (2005 - 2016), EBMT | Ian Wu, Koh LP et al. ASH 2020. Ruggeri A, et al. Leukemia 2015. |
| Sequential Transplant Using Matched Related/Unrelated Donor | Haematological Cancers | ~60% at 3 years (2006 - 2020) | ~55% at 3 years (2007 - 2019) (EBMT) | Chong LL, Koh LP, et al. ASH 2020. Malard F, et al. BBMT 2017 |
References:
(Information is correct as at July 2022)
The following table shows the survival information of patients diagnosed with non–small cell lung cancer (NSCLC) at NCIS between 2015 to 2019. The 5-year survival rate reflects the percentage of these patients who remain alive at the 5th year, according to their diagnosed NSCLC stage.
